Your shopping cart is currently empty

TXNIP-IN-1 is an inhibitor of the TXNIP-TRX complex and used in the research of TXNIP-TRX complex associated metabolic disorder (diabetes), cardiovascular disease, or inflammatory disease.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $135 | In Stock | In Stock | |
| 5 mg | $289 | In Stock | In Stock | |
| 10 mg | $438 | In Stock | In Stock | |
| 25 mg | $726 | In Stock | In Stock | |
| 50 mg | $987 | In Stock | In Stock | |
| 100 mg | $1,380 | In Stock | In Stock | |
| 500 mg | $2,770 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $373 | In Stock | In Stock |
| Description | TXNIP-IN-1 is an inhibitor of the TXNIP-TRX complex and used in the research of TXNIP-TRX complex associated metabolic disorder (diabetes), cardiovascular disease, or inflammatory disease. |
| In vitro | TXNIP-IN-1 bocks high glucose (HG induced) TXNIP-TRX complex formation.In monocytes, TXNIP-IN-1 (1.25-5 μM) reduces HG-induced expression of TNF . In THP1 cells,TXNIP-IN-1 (1.25-5 μM; 72 hours) inhibits TXNIP mRNA expression . TXNIP-IN-1 (0.3-10 μM; 72 hours) inhibits TXNIP mRNA expression in murine RAW macrophages. In MIN6 cells, TXNIP-IN-1 (5-20 μM; 72 hours) decreases TXNIP but not TNF-alpha mRNA levels . TXNIP-IN-1 (0.62-5 μM; 72 hours) affects TXNIP and TNF-alpha mRNA expression in human pancreas 1.1B4 beta cells. TXNIP-IN-1 (5 μM; 16-72 hours) inhibits c-TRX interaction in THP1 cells cultured in 25mM glucose. TXNIP-IN-1 targets TXNIP mRNA in human pancreatic islets. |
| Molecular Weight | 248.23 |
| Formula | C12H12N2O4 |
| Cas No. | 1268955-50-5 |
| Smiles | CC(C)C(N1C(=O)c2ccncc2C1=O)C(O)=O |
| Relative Density. | 1.410 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 40 mg/mL (161.14 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (8.06 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.